These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 30269007)

  • 1. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
    Gupta N; Huang TT; Horibata S; Lee JM
    Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Smith HL; Willmore E; Prendergast L; Curtin NJ
    Br J Cancer; 2024 Sep; 131(5):905-917. PubMed ID: 38965423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
    Ngoi NY; Sundararajan V; Tan DS
    Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
    Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
    Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
    [No Abstract]   [Full Text] [Related]  

  • 8. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
    Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
    Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway.
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188633. PubMed ID: 34619333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
    Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
    Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib-Resistant
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [